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Abstract 
Background:  Liver dialysis, molecular adsorbent recirculating system (MARS) particularly, has been 
used in liver failure to bridge to transplantation.  We expanded the indication for MARS to patients with 
acute shock liver failure and cardiopulmonary failure on ECMO, aiming to improve survival to wean 
from ECMO. 
Methods:  An IRB approved, retrospective chart analysis of patients on ECMO between 2010 and 2015 
found 28 patients who met the criteria for acute liver failure, diagnosed by hyperbilirubinemia (total 
bilirubin ≥ 10 mg/dl), or by elevated transaminase (alanine transaminase [ALT] >1000 IU/L).  Among 
those, 14 patients underwent MARS treatment (Group M) and 14 patients were supported with optimal 
medical treatment without MARS (Group C).  Patient characteristics, liver function and survival were 
compared between groups. 
Results:  Demographics, clinical risk factors, and pre-ECMO laboratory data were identical between the 
groups.  MARS was utilized continuously for 8 ± 9 days in Group M.  Total bilirubin, ALT, and 
international normalized ratio (INR) were improved significantly in Group M.  There were no 
MARS-related complications.  Survival to wean from ECMO for Group M was 64% (9/14) versus 21% 
(3/14) for Group C, p = 0.02.  Death related to worsening liver dysfunction during ECMO was 40% (2/5 
deaths) in Group M and 100% (11/11 deaths) in Group C, p=0.004.  Thirty-day survival after ECMO 
was 43% (6/14) in Group M and 14% (2/14) in Group C, p=0.09. 
Conclusions: MARS therapy on ECMO patients safely accelerated recovery of liver function and 
improved survival to wean from ECMO, without increasing complications. 
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Introduction 
 In cases of acute-on-chronic liver failure, liver dialysis, specifically the molecular adsorbent 
recirculating system (MARS) has been used to bridge patients to liver transplantation and is known to 
improve outcomes of liver transplantation. 1, 2  MARS therapy consists of filtering blood through a 
specialized albumin-containing dialysate to remove protein-bound toxins.  Blood is filtered in-line 
through a charcoal column and an anion exchanger column before return.  This system allows for the 
removal of molecules such as bile acids, bilirubin, and cytokines, as well as water-soluble toxins such as 
creatinine and ammonia. 3  By removing both protein-bound and water-soluble toxins, MARS facilitates 
liver recovery and also may prevent further deterioration of other organ systems. 4 
Overall ECMO mortality is reported to be 47%-61%, 5 and one of the primary causes of death 
for extracorporeal membrane oxygenation (ECMO) patients is refractory multiple-organ failure including 
acute liver failure. Acute liver failure (ALF) occurs in ~13-19% of the ECMO population. 6  In our 
institution, we expanded the indication for MARS to another patient population – cardiopulmonary failure 
patients requiring ECMO who have developed acute liver failure.  This retrospective study was 
performed to evaluate the questions: can MARS improve acute liver failure on ECMO safely, and to 
evaluate the survival of the patients with or without MARS treatments on ECMO. 
Methods 
After approval from the institutional review board, medical records of consecutive ECMO 
patients between August 2010 and March 2015 were retrospectively reviewed to identify the incidence of 
liver dysfunction while on ECMO.  The only exclusion criterion was any ECMO patient in whom 
treatment was deemed futile within the first 24 hours of cannulation.  Veno-arterial ECMO (VA ECMO) 
was primarily used for refractory cardiac failure, 7 and veno-veno ECMO (VV ECMO) was primarily 
used for refractory respiratory failure, 8 detailed in the previous publications. 
Among the 133 ECMO patients during the study period, 28 patients (21%) were found to have 
acute liver failure, defined as total bilirubin ≥ 10 mg/dl or alanine aminotransferase (ALT) ≥ 1000 IU/L. 
Further details for inclusion data are shown in Table 1.  These patients were included if they met the 
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criteria for liver failure despite correction of an underlying process such as hemolysis or obstructive 
cholangitis.  The rounding attending physician made the decision for the initiation of MARS.  Of the 28 
studied patients, 14 patients (Group M) underwent liver dialysis using MARS (Gambro, Lakewood, CO, 
USA), and 14 patients (Group C) were supported with optimal medical therapies.  Medical therapies for 
Group C and Group M included maintenance of appropriate ECMO flow (body surface area x 2.2 L/min 
or above), lactulose treatment, nutrition support (via either enteral tube feeding or total parenteral 
nutrition), and avoidance of hepatotoxic medications, including statins and Amiodarone.  In Group M, 
the MARS system was run with blood flow rates between 100 – 150 ml/min using a standard dual lumen 
dialysis catheter placed in the femoral vein, using a 25% albumin dialysate.  Treatment was continued 
until recovery of liver function; specifically, total bilirubin returned to ≤ 7 mg/dl and/or ALT ≤ 500 IU/L, 
or the time of ECMO removal.  No patient was placed on MARS with the intention to bridge to liver 
transplantation.  The MARS circuit was maintained continuously, excepting for circuit changes needed 
every 24 hours.  Anticoagulation was maintained for a PTT between 45-55 seconds for ECMO 
regardless the presence of MARS. 
Primary study endpoints were survival to wean from ECMO and 30-day survival after ECMO 
decannulation.  A secondary endpoint was the trend of liver function (total bilirubin, alanine 
aminotransferase [ALT], and international normalized ratio [INR]) during treatments. In addition, 
bleeding complications and disseminated intravascular coagulopathy (DIC) were monitored during 
ECMO. 
 Data were expressed as number with percent and mean with standard deviations.  Statistical 
analysis consisted of two group comparisons between Group M and Group C using Student t-tests for 
continuous variables and chi-square or Fisher's exact tests for categorical variables.  A p-value less than 
0.05 was considered to be significant. 
Results 
There were 14 patients in Group M and 14 patients in Group C.  Baseline characteristics, 
pre-ECMO clinical risk factors, and laboratory data were compared and were similar between the two 
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groups (Table 2).  Group C and Group M both include patients from overlapping timeframes – Group C 
was not from an era prior to availability of MARS therapy. 
The laboratory values for the patients at the time criteria of acute liver failure were met are shown 
in Table 3.  MARS therapy was initiated in mean of 5 ± 4 days after ECMO was started in Group M.  
The length of ECMO before the patients met the criteria for acute liver failure in Group C was 7 ± 6 days. 
The average length of MARS on ECMO was 8 ± 9 days (range 1 – 32 days).  After 3 days, total bilirubin 
average for Group M (n=12) decreased by 5.1 ± 12 mg/dL, while Group C (n=9) average total bilirubin 
increased 2.6 ± 9 mg/dl (p = 0.11).  By day 7, the average total bilirubin for Group M (n=11) had 
decreased by 7.9 ± 15 mg/dL, while in the same time period the average bilirubin for Group C had 
increased by 7.5 ± 6 mg/dL (p = 0.01).  By day 3, ALT for Group M had decreased by 1310 ± 1851 IU/L 
while in Group C the ALT had increased by 320 ± 733 IU/L (p = 0.01).  Similarly, by day 3, INR for 
Group M had decreased by 0.32 ± 0.5 while in Group C the INR had only decreased by 0.05 ± 0.4 IU/L (p 
= 0.19).  These trends are shown in Figure 1.  Furthermore, these trends continued for the duration of 
ECMO, as shown in Figure 2. 
Bleeding complications while on ECMO, defined as bleeding that required invasive intervention, 
were 79% (n=11) in both groups.  The most common etiologies were gastrointestinal bleeding, epistaxis, 
and cannula site bleeding; this breakdown was consistent across both groups.  Incidence of disseminated 
intravascular coagulopathy (DIC) was 14% (n=2) for Group M vs. 21% (n=3) for Group C (p = 0.62).  
The causes of DIC were multifactorial, and did not appear to be related to MARS treatment.  There was 
no MARS-related sepsis.  There were no mechanical ECMO complications, such as flow competition, 
during MARS. 
Survival to wean from ECMO was 64% (9/14) in Group M and 21% (3/14) in Group C, p=0.02 
(Figure 3).  Death related to worsening liver dysfunction was 40% (2/5 deaths) in Group M and 100% 
(11/11 deaths) in Group C (p=0.004).  Of the patients to survive to wean off of ECMO, only 2 patients 
(22%) in Group M continued MARS treatment and in both of those cases, liver function was eventually 
normalized. Five patients (56%) in Group M weaned to a permanent mechanical circulatory support 
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device, versus only 1 patient (33%) in Group C (p=0.06).  Thirty days survival after ECMO 
decannulation was 43% (6/14) in Group M and 14% (2/14) in Group C, p=0.09 (Figure 3).  The patients 
in Group M who survived to wean off of ECMO all recovered liver function, therefore liver failure was 
not a contributing factor to their death. 
Discussion 
The research on MARS for patients with cardiopulmonary failure requiring ECMO is very sparse.  
Zitterman 9 used MARS for liver failure due to cardiogenic shock following cardiac surgery.  The study 
involved 197 post-operative patients with a bilirubin > 6 mg/dl, of which 20 (10%) required ECMO.  
They reported many complications (gastrointestinal, respiratory, and infections) and had an in-hospital 
mortality rate of 66% (n=129) after MARS initiation.  Total bilirubin did not decrease in their cohort 
overall, though the survivors did show a significant decrease compared with non-survivors.  Based on 
APACHE II, SOFA, and SAPS II scores, they determined a predicted mortality of 100%, which improved 
to 34% (n=68) with MARS usage. 9  Survival within the ECMO population specifically was not 
discussed.  In the only study specifically involving ECMO patients, Peek 10reviewed their series of 
ECMO prior to the use of MARS and found that no ECMO patients at their institution survived once 
severe liver dysfunction (total bilirubin > 23 mg/dl) developed and only 10% survived if bilirubin was 
greater than 17 mg/dl.  With this prior survival data, Peek et al. changed their indication to initiate 
MARS to include patients with bilirubin greater than 17 mg/dl.  Using MARS with this indication, 2/5 
(40%) of the patients survived, compared to a prediction of 100% mortality. 10 
While we were able to show that survival was improved in Group M versus Group C, it is equally 
important to note that complications from using the treatment did not arise. In the two cases of DIC 
within the treatment group, the causes were multifactorial, and did not appear to be related to MARS.  
One of the patients was an acetaminophen overdose who was never stabilized following cardiac arrest and 
ECMO, while the other was due to possible hemolysis after a prolonged course on ECMO requiring three 
different mechanical circulatory support devices.  Complications occurring in the ICU course for both 
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groups were similar, and specifically, incidence of DIC was similar, with no indication MARS was the 
cause of any case of DIC. 
In another study, Rittler11 reviewed 5 patients after Whipple’s operation or liver transplantation 
complicated with liver failure and gram-negative sepsis and/or fungemia.  In that particular population 
with liver failure accompanied by sepsis, despite the use of MARS, no patients survived.  They also 
reported significant bleeding side effects in this group, although they were using heparin to maintain PTT 
> 50 seconds to anti-coagulate the MARS system.  They concluded that sepsis-related liver failure might 
not be an indication for MARS therapy. 11   In our study, sepsis was not the primary cause of shock liver, 
but 2 patients in Group M (14%) and 3 patients in Group C (21%) were septic during the study.  The 
patients in Group M did not have any of the complications seen in the Rittler study.  Those 2 patients in 
Group M survived, while none of the 3 septic patients in Group C survived to wean off of ECMO (p = 
0.03).  
Prior studies on the effectiveness of MARS in the acute-on-chronic liver failure population have 
found that treatment can improve hemodynamic status or have an effect on coagulation.1,12 We found an 
improvement of INR while on MARS (Figures 1 & 2); however, we were not able to identify the 
hemodynamic improvement, maybe because hemodynamics were already supported by ECMO.  
Our study supports that acute liver failure during ECMO can be supported with MARS and that 
once liver functions are normalized, no additional MARS are necessary.  Additionally, the fact that five 
of the patients in Group M were implanted with ventricular assist devices points to recovery of end organ 
function, without any neurological deficits.  Without recovery of liver function, these patients would not 
have been device candidates. 
The decision to start MARS treatment was most often based upon increased total bilirubin.  
However, we found the Group M had significantly higher liver enzymes as well. Group M also met 
criteria for acute liver failure sooner after ECMO initiation (3 ± 3 days) than Group C (6 ± 7 days).  By 
day 3 after inclusion, only 70% (10/14) of the patients in Group C were alive, dropping to 36% (5/14) 
survival by day 7.  This is compared to 79% (11/14) survival to day 7 in Group M (p=0.02). This 
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illustrates that medical therapy alone is not enough to stop the progression from acute liver failure to 
death in this patient population.  All patients in the treatment group showed total bilirubin that trended 
downward by day 3, and continued downward until MARS was stopped (Figure 2) - suggesting that liver 
function recovered. 
The main limitation of this study was small sample size, retrospective, single center 
experience.  The decision to initiate MARS therapy was a clinical judgment base on the attending 
physician’s assessment at the bedside and thus the two groups were not randomized.  This study does 
not address discharge survival data.  Because many surviving patients in Group M went on to receive 
permanent mechanical circulatory support devices, they required a more prolonged hospital stay. Survival 
to discharge data in that group would have many other confounding variables from those other forms of 
mechanical support devices as well as from the prolonged hospital stay.  Going forward, research is 
needed to further refine the appropriate patient selection criteria and to initiate optimal treatment 
guidelines, as well as to determine if MARS therapy increases survival to discharge. 
Study Highlights 
 At this time, the use of MARS liver dialysis for acute-on-chronic liver failure to prolong 
survival until transplantation has been accepted. 1,2  However, the research on expanding the use of 
MARS to other patient populations has demonstrated mixed results, regarding both safety and efficacy.  
This study looked at a specific population – multiple-organ failure patients on ECMO with acute liver 
failure – in order to determine if MARS could improve survival to wean off ECMO.  The results showed 
that without increasing complications, MARS could safely improve survival outcomes and accelerate 
liver recovery within this patient population. ECMO is widely used to support the patient while the heart 
and/or lungs recover, the results of this study indicate that the liver can recover in the same manner if the 
patient is supported with the MARS liver dialysis system. 
Conclusion 
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The results of this study show that the MARS system for liver dialysis can safely and 
effectively be used for acute liver failure in cardiopulmonary failure patients who are being supported by 
ECMO in order to accelerate liver recovery.  Survival benefit by MARS was clearly demonstrated, 
without any additional increase in complications.  
Financial Conflict of Interest Disclosure 
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Table 1: Inclusion Criteria for MARS on ECMO. 
 
 
Group M 
(N=14) 
Group C 
(N=14) 
P - value 
Hyperbilirubinemia (>10mg/dl) 11 14 0.0668 
Increased ALT (>1000 IU/L) 3 0 0.0668 
Hyperbilirubinemia (>10mg/dl) and increased ALT (>1000 IU/L) 4 2 0.3570 
 
ALT: alanine aminotransferase.  Data expressed as number. 
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Table 2: Baseline Demographics and Indications for ECMO. 
 
 
Group M (n=14) Group C (n=14) P- value 
Age (years) 44 ± 16 54 ± 13 0.0811 
Male 5 (36%) 9 (64%) 0.1306 
Body mass index (kg/m2) 27 ± 6 28 ± 5 0.6359 
Weight (kg) 76 ± 26 78 ± 21 0.8246 
Clinical risk factors 
   
Smoker 5 (36%) 3 (21%) 0.4028 
E-CPR 3 (21%) 2 (14%) 0.6217 
Diabetes mellitus 4 (29%) 4 (29%) 1.0000 
Coronary artery disease 4 (29%) 8 (57%) 0.1266 
Acute myocardial infarction 3 (21%) 1 (7%) 0.2801 
Primary respiratory failure 3 (21%) 4 (29%) 0.6625 
Primary Diagnosis for ECMO    
Acute on chronic heart failure 4 (29%) 3 (21%) 0.6625 
Malignant Arrhythmia 2 (14%) 0 (0%) 0.1422 
Takotsubo Cardiomyopathy 0 (0%) 2 (14%) 0.1422 
Bacterial Pneumonia 0 (0%) 1 (7%) 0.3085 
Interstitial Pneumonitis 1 (7%) 0 (0%) 0.3085 
Aspiration Pneumonia 0 (0%) 2 (14%) 0.1422 
Viral Pneumonia 0 (0%) 1 (7%) 0.3085 
Post-cardiotomy failure 5 (35%) 4 (29%) 0.6857 
Acute Myocardial Infarction 2 (14%) 1 (7%) 0.5412 
Pre ECMO laboratory data 
   
Creatinine (mg/dl) 1.7 ± 1 1.8 ± 0.99 0.7522 
Total bilirubin (mg/dl) 2.9 ± 3.1 3.3 ± 3.2 0.7611 
Aspartate aminotransferase (IU/L) 3198 ± 9997 784 ± 1610 0.3984 
Alanine aminotransferase (IU/L) 770 ± 1884 351 ± 751 0.4642 
Alkaline phosphatase (IU/L) 139 ± 100 107 ± 78 0.3704 
Lactate (mg/dl) 7.4 ± 7.5 6.6 ± 5.2 0.7521 
INR 1.99 ± 1.10 1.98 ± 0.89 0.9589 
ECMO data 
   
Veno-arterial ECMO 11 (79%) 11 (79%) 1.0000 
Veno-venous ECMO 3 (21%) 3 (21%) 1.0000 
Length of ECMO (days) 17 ± 9 12 ± 10 0.1761 
ECMO complications 
   
Bleeding 10 (71%) 11 (79%) 0.6625 
Disseminated intravascular coagulopathy 2 (14%) 3 (21%) 0.6217 
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DIC: disseminated intravascular coagulopathy; E-CPR: extra-corporeal membrane oxygenation assisted 
cardiopulmonary resuscitation; ECMO: extra-corporeal membrane oxygenation; INR: international 
normalized ratio 
Data are expressed as mean ± standard deviation or as number (percentage). 
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Table 3. Laboratory Data at Inclusion.  
 
 
Group M 
(N=14) 
Group C 
(N=14) 
P-value 
Duration of ECMO before MARS in group M and 
before met criteria of acute liver failure in group C 
(days) 
5 ± 4 7 ± 6  0.31 
On CVVHD pre-MARS 6 (43%) 9 (64%) 0.2556 
Creatinine (mg/dl) 1.3 ± 0.5 1.3 ± 0.7 1.0000 
Bilirubin (mg/dl) 10.5 ± 3.3 11.8 ± 1.9 0.2128 
Aspartate aminotransferase (IU/L) 9412 ± 13430 492 ± 698 0.0199 
Alanine aminotransferase (IU/L) 2271 ± 2577 193 ± 210 0.0058 
Alkaline phosphatase (IU/L) 162 ± 83 113 ± 47 0.0656 
Lactate (mg/dl) 8.2 ± 8.0 6.8 ± 7.5 0.6369 
INR  1.86 ± 0.57 1.52 ± 0.43 0.0865 
MELD Score  29 ± 6 30 ± 5 0.6359 
 
CVVHD: continuous veno-veno hemodialysis; ECMO: extra-corporeal membrane oxygenation; INR: 
international normalized ratio; MARS: molecular adsorbent recirculating system; MELD Score: Model 
for End-Stage Liver Disease Score. 
Data expressed as mean ± standard deviation or as number (percentage). 
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Legends of Figures 
Figure 1: 1a) Trends of total bilirubin; 1b) Trends of alanine aminotransferase (ALT); 1c) Trends of 
international normalized ratio (INR). 
Figure 2: 2a) Trends of total bilirubin in Group M; 2b) Trends of alanine aminotransferase (ALT) in 
Group M; 2c) Trends of international normalized ratio (INR) in Group M. 
Figure 3:  Survival data. 
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